722. Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a University—Oregon, 2015
Session: Poster Abstract Session: Vaccines: Adolescent HPV and Meningococcal
Thursday, October 27, 2016
Room: Poster Hall
  • 102016 OR carriage poster.pdf (484.2 kB)
  • Background: Serogroup B meningococcal disease is a life-threatening illness for which asymptomatic carriers are the primary source of transmission. While immunogenicity data suggest serogroup B vaccines (3-dose MenB-FHbp [Trumenba®] and 2-dose MenB-4C [Bexsero®]) protect individuals from disease, few data exist on whether these vaccines reduce meningococcal carriage and promote herd immunity. We assessed carriage following these vaccines’ use in response to a serogroup B meningococcal disease outbreak at an Oregon university.

    Methods: A convenience sample of students recommended for serogroup B vaccination provided oropharyngeal swabs and completed questionnaires assessing carriage risk factors during three carriage surveys conducted during serogroup B vaccination campaigns at the university. Isolates were tested by real-time PCR, slide agglutination, and whole genome sequencing. Vaccination was verified via university records and the state immunization registry. Prevalence ratios (PR) were calculated using multivariate Poisson regression with generalized estimating equations.

    Results: Carriage was assessed for 2936 students; 288 participated in multiple surveys. Total meningococcal and genotypic serogroup B carriage prevalences were 11–17% and 1.2%–2.1% each round, respectively; no participants carried the outbreak-associated strain. Male gender (PR 1.4, 95% confidence interval [CI] 1.2–1.7); age 19–20 (PR 1.4, 95% CI 1.1–1.8) or 23–29 (PR 0.65, 95% CI 0.40–1.0) years; having ≥3 roommates (PR 1.3, 95% CI 1.1–1.6); attending parties, bars, or nightclubs at least once weekly (PR 2.4, 95% CI 1.9–2.9); smoking (PR 1.6, 95% CI 1.4–2.0); antibiotic use in the past 30 days (PR 0.50, 95% CI 0.33–0.76); and second-round participation (PR 1.4, 95% CI 1.2–1.6) were associated with meningococcal carriage; receiving 1–2 doses of MenB-FHbp or MenB-4C was not.

    Conclusion: Overall meningococcal carriage was not associated with receiving 1–2 doses of MenB-FHbp or MenB-4C among sampled students and serogroup B carriage did not decrease over time. Analysis of a fourth carriage survey to assess the impact of 3 MenB-FHbp doses is ongoing. These data will inform policies for using serogroup B meningococcal vaccines.

    Lucy Mcnamara, PhD, MS1, Jennifer Thomas, Phd1, Jessica Macneil, MPH1, Michael Day, MPA2, Emily Fisher, MD2, Stacey W. Martin, MS1, Tasha Poissant, MPH2, Xin Wang, PhD1 and Anna M. Acosta, MD3, (1)National Center for Immunization and Respiratory Diseases, CDC, Atlanta, GA, (2)Oregon Health Authority, Portland, OR, (3)Meningitis and Vaccine Preventable Diseases, Centers for Disease Control and Prevention, Atlanta, GA


    L. Mcnamara, None

    J. Thomas, None

    J. Macneil, None

    M. Day, None

    E. Fisher, None

    S. W. Martin, None

    T. Poissant, None

    X. Wang, None

    A. M. Acosta, None

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.